EricaDahlWarlickMD

Oncology • Minneapolis, MN

Hematologic Oncology

Assistant Professor, Medicine, University of Minnesota Medical School

Join to view full profile

Dr. Warlick is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Warlick's full profile

Already have an account?

Office
420 Delaware St SE
# Mmc
Minneapolis, MN 55455
Phone+1 612-624-0123

Fax+1 612-676-4004

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
Johns Hopkins UniversityResidency, Internal Medicine, 2001 - 2004
University of Minnesota Medical SchoolClass of 2001

Certifications & Licensure

MN State Medical License 2007 - 2025
MD State Medical License 2004 - 2007
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy Start of enrollment: 2002 Mar 26
Terminated
Phase 2
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2009 Jan 01
Terminated
Phase 2
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
Terminated
Phase 3
Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes Start of enrollment: 2013 Mar 01
Completed
Phase 2
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
Allo HSCT Using RIC for Hematological Diseases Start of enrollment: 2017 Mar 09
Completed
Phase 2
Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma
No longer available
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

34 citations
Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic Hematopoi...
Erica D. Warlick, Todd E. DeFor, Bruce R. Blazar, Linda J. Burns, Michael R. Verneris
Biology of Blood and Marrow Transplantation. 2012-03-01
439 citations
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott, Marcelo C. Pasquini, Brent R. Logan, Juan Wu, Steven M. Devine
Journal of Clinical Oncology. 2017-02-13
51 citations
Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia.
Celalettin Ustun, Elizabeth L. Courville, Todd E. DeFor, Michelle M Dolan, Nicole Randall
Biology of Blood and Marrow Transplantation. 2016-04-01

Journal Articles

Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment Kinetics
Erhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica

Abstracts/Posters

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)
Erica D. Warlick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Predicted Leukocyte Telomere Length and Risk of Myeloid Neoplasms
Erica D. Warlick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
Erica D. Warlick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults
Erica D. Warlick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
History of Autoimmune Disease Is Associated with Increased Risk for Myelodysplastic Syndromes
Erica D. Warlick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disea...
Erica D. Warlick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multip...
Erica D. Warlick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills Non-Small Cell Lung Cancer (NSCLC) Tumor CellsOctober 22nd, 2019
GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected CellsOctober 3rd, 2019
GT Biopharma Announces HIV Trike™ Data to Be PublishedSeptember 26th, 2019
Join now to see all